Electra Therapeutics: Is a price target of 32 USD paving the way for the first FDA approval for mHLH?
Reading Time: 2 minutes
The business model focuses on SIRP immunotherapies for inflammatory and oncological diseases. Jefferies issues a buy recommendation with a price target of 32 USD due to the potential of the lead candidate Ipsoprubart. The ongoing Phase 3 study offers the chance for the first FDA approval for malignancy-associated HLH. Focus on Targeted SIRP Therapies The business model of the biotechnology company Electra Therapeutics (ETRA) centers on the development of novel therapeutics for immunological diseases and cancer. At the core are SIRP-targeted antibodies...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
